XenoPort Inc. and GlaxoSmithKline Plc won U.S. approval for a new treatment for restless legs syndrome after more than a year of delays. XenoPort’s shares climbed 57 percent in extended trading after the announcement.
BusinessWeek.com -- Top News, Business Week
Wed, 04/06/2011 - 9:26pm
XenoPort Inc. and GlaxoSmithKline Plc won U.S. approval for a new treatment for restless legs syndrome after more than a year of delays. XenoPort’s shares climbed 57 percent in extended trading after the announcement.